World Novelty: Artificial HPL Solution
Image announcing the development of first artificial HPL composition
PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. The company has developed a proprietary method to transform lab-grown platelets into a powerful cell culture supplement.
Aachen, Germany, 8 May 2025 – PL BioScience GmbH, a German life science company
specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion,
today announced the first-ever production of an artificial HPL cell culture solution. In partnership
with the Korean biotech DewCell Biotherapeutics (DewCell), the first company to generate
artificial platelets from stem cells in a reactor, PL BioScience has developed a proprietary method
to transform these lab-grown platelets into a powerful cell culture supplement. Produced in
Germany with raw material from DewCell, this new technology offers a scalable, safe, and animal-
free alternative to Fetal Calf/Bovine Serum (FCS/FBS) and donor-derived, natural HPL for
regenerative medicine, cell therapy, and biopharma applications. A patent for the process has
been filed.
“Cell culture innovation is crucial for advancing modern medicine, drug discovery, and
understanding complex biological systems,” said Dr. Hatim Hemeda, Chief Executive Officer of
PL BioScience. “We are proud to contribute to the field with the very first, scalable artificial HPL
solution that, in the mid-term, can be produced in a nearly unlimited supply to meet the growing
biopharmaceutical industry needs.”
“We are confident that the combination of DewCell's innovative technology and our cell culture
expertise will usher in a new era in the field of regenerative medicine and cell therapy
manufacturing,” he added.
Dr. Hemeda will present the innovative new technology in an oral presentation at the International
Society for Cell & Gene Therapy (ISCT) conference in New Orleans:
Innovating A Xeno-Free Revolution for Cell Therapies – Human Platelet Lysate
May 8, 2025, 6:15 PM CT, Global Showcase Theater B
HPL is a safe, high-performance cell culture supplement that can be used as an alternative to
FBS/FCS. HPL is manufactured from donated human blood platelets that are outdated and no
longer safe for transfusion, making them a sustainable but limited source to produce HPL. With
its proprietary technology for the synthetic production of HPL in conjunction with DewCell’s
artificial platelet technology, PL BioScience can overcome this limitation and provides a fully
scalable, high-performing cell culture supplement for biopharmaceutical applications.
